Primary sclerosing cholangitis with equivocal cytology: Fluorescence in situ hybridization and serum ca 19-9 predict risk of malignancy

Cancer Cytopathology

Volumn 121, Issue 12, 2013, Pages 708-717

  Fritcher, Emily G Barr ^a   Voss, Jesse S ^a   Jenkins, Sarah M ^a   Lingineni, Ravi K ^a   Clayton, Amy C ^a   Roberts, R ^a   Halling, Kevin C ^a   Talwalkar, Jayant A ^a   Gores, Gregory J ^a   Kipp, Benjamin R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Biliary brushing; Cholangiocarcinoma; Pancreatic adenocarcinoma; Polysomy; Stricture

Indexed keywords

CA 19-9 ANTIGEN; URSODEOXYCHOLIC ACID; TUMOR MARKER;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER RISK; CONTROLLED STUDY; CYTODIAGNOSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GALLBLADDER CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PANCREAS ADENOCARCINOMA; PREDICTIVE VALUE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; BILE DUCT TUMOR; BILIARY BRUSHING; BLOOD; COHORT ANALYSIS; CONFIDENCE INTERVAL; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KAPLAN MEIER METHOD; METHODOLOGY; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; POLYSOME; POLYSOMY; PRECANCER; SCLEROSING CHOLANGITIS; STRICTURE; YOUNG ADULT; PROCEDURES;

BILIARY BRUSHING; CHOLANGIOCARCINOMA; PANCREATIC ADENOCARCINOMA; POLYSOMY; STRICTURE;

ADULT; AGED; BILE DUCT NEOPLASMS; BIOPSY, NEEDLE; CA-19-9 ANTIGEN; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; CHOLANGITIS, SCLEROSING; COHORT STUDIES; CONFIDENCE INTERVALS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; POLYRIBOSOMES; PRECANCEROUS CONDITIONS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84885662199     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21331     Document Type: Article

References (36)

1. Gossard AA, Lindor KD. A 42-year-old woman with a new diagnosis of sclerosing cholangitis. Clin Gastroenterol Hepatol. 2012;10: 593-597.
2. Chapman MH, Webster GJ, Bannoo S, Johnson GJ, Wittmann J, Pereira SP. Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience. Eur J Gastroenterol Hepatol. 2012;24:1051-1058.
3. Furmanczyk PS, Grieco VS, Agoff SN. Biliary brush cytology and the detection of cholangiocarcinoma in primary sclerosing cholangitis: evaluation of specific cytomorphologic features and CA19-9 levels. Am J Clin Pathol. 2005;124:355-360.
4. Govil H, Reddy V, Kluskens L, et al. Brush cytology of the biliary tract: retrospective study of 278 cases with histopathologic correlation. Diagn Cytopathol. 2002;26:273-277.
5. Harewood GC, Baron TH, Stadheim LM, Kipp BR, Sebo TJ, Salomao DR. Prospective, blinded assessment of factors influencing the accuracy of biliary cytology interpretation. Am J Gastroenterol. 2004;99:1464-1469.
6. Lee JG. Brush cytology and the diagnosis of pancreaticobiliary malignancy during ERCP. Gastrointest Endosc. 2006;63:78-80.
7. Mahmoudi N, Enns R, Amar J, AlAli J, Lam E, Telford J. Biliary brush cytology: factors associated with positive yields on biliary brush cytology. World J Gastroenterol. 2008;14:569-573.
8. Chadwick BE. Beyond cytomorphology: expanding the diagnostic potential for biliary cytology. Diagn Cytopathol. 2012;40:536-541.
9. Moreno Luna LE, Kipp B, Halling KC, et al. Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology. 2006;131:1064-1072.
10. Baudis M. Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis of chromosomal CGH data. BMC Cancer. 2007;7:226.
11. Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463:899-905.
12. Kipp BR, Barr Fritcher EG, Pettengill JE, Halling KC, Clayton AC. Improving the accuracy of pancreatobiliary tract cytology with fluorescence in situ hybridization: a molecular test with proven clinical success [published online ahead of print April 30, 2013]. Cancer (Cancer Cytopathol). doi: 10.1002=cncy.21303.
13. Fritcher EG, Kipp BR, Halling KC, et al. A multivariable model using advanced cytologic methods for the evaluation of indeterminate pancreatobiliary strictures. Gastroenterology. 2009;136:2180-2186.
14. Bangarulingam SY, Bjornsson E, Enders F, et al. Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology. 2010;51:174-180.
15. Barr Fritcher EG, Kipp BR, Voss JS, et al. Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma. Am J Gastroenterol. 2011;106:2023-2028.
16. Cohen MB, Wittchow RJ, Johlin FC, Bottles K, Raab SS. Brush cytology of the extrahepatic biliary tract: comparison of cytologic features of adenocarcinoma and benign biliary strictures. Mod Pathol. 1995;8:498-502.
17. Renshaw AA, Madge R, Jiroutek M, Granter SR. Bile duct brushing cytology: statistical analysis of proposed diagnostic criteria. Am J Clin Pathol. 1998;110:635-640.
18. Barr Fritcher EG, Kipp BR, Slezak JM, et al. Correlating routine cytology, quantitative nuclear morphometry by digital image analysis, and genetic alterations by fluorescence in situ hybridization to assess the sensitivity of cytology for detecting pancreatobiliary tract malignancy. Am J Clin Pathol. 2007;128:272-279.
19. Kipp BR, Stadheim LM, Halling SA, et al. A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol. 2004;99: 1675-1681.
20. Levy MJ, Baron TH, Clayton AC, et al. Prospective evaluation of advanced molecular markers and imaging techniques in patients with indeterminate bile duct strictures. Am J Gastroenterol. 2008; 103:1263-1273.
21. Halling KC, Kipp BR. Fluorescence in situ hybridization in diagnostic cytology. Hum Pathol. 2007;38:1137-1144.
22. Levy C, Lymp J, Angulo P, Gores GJ, Larusso N, Lindor KD. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci. 2005;50: 1734-1740.
23. Layfield LJ, Cramer H. Primary sclerosing cholangitis as a cause of false positive bile duct brushing cytology: report of two cases. Diagn Cytopathol. 2005;32:119-124.
24. Rabinovitz M, Zajko AB, Hassanein T, et al. Diagnostic value of brush cytology in the diagnosis of bile duct carcinoma: a study in 65 patients with bile duct strictures. Hepatology. 1990;12(4 pt 1): 747-752.
25. Stewart CJ, Mills PR, Carter R, et al. Brush cytology in the assessment of pancreaticobiliary strictures: a review of 406 cases. J Clin Pathol. 2001;54:449-455.
26. Adamsen S, Olsen M, Jendresen MB, Holck S, Glenthoj A. Endobiliary brush biopsy: intra-and interobserver variation in cytological evaluation of brushings from bile duct strictures. Scand J Gastroenterol. 2006;41:597-603.
27. Fritcher EG, Halling KC. Advanced cytologic approaches for the diagnosis of pancreatobiliary cancer. Curr Opin Gastroenterol. 2010; 26:259-264.
28. Boldorini R, Paganotti A, Sartori M, et al. Fluorescence in situ hybridisation in the cytological diagnosis of pancreatobiliary tumours. Pathology. 2011;43:335-339.
29. Gonda TA, Glick MP, Sethi A, et al. Polysomy and p16 deletion by fluorescence in situ hybridization in the diagnosis of indeterminate biliary strictures. Gastrointest Endosc. 2012;75:74-79.
30. Charatcharoenwitthaya P, Enders FB, Halling KC, Lindor KD. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology. 2008;48:1106-1117.
31. Chapman WC. Fluorescent in situ hybridization testing in primary sclerosing cholangitis: useful testing or a random chance result? Hepatology. 2010;51:16-19.
32. DeHaan RD, Kipp BR, Smyrk TC, Abraham SC, Roberts LR, Halling KC. An assessment of chromosomal alterations detected by fluorescence in situ hybridization and p16 expression in sporadic and primary sclerosing cholangitis-associated cholangiocarcinomas. Hum Pathol. 2007;38:491-499.
33. Chalasani N, Baluyut A, Ismail A, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter casecontrol study. Hepatology. 2000;31:7-11.
34. Nichols JC, Gores GJ, LaRusso NF, Wiesner RH, Nagorney DM, Ritts RE Jr. Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clin Proc. 1993;68:874-879.
35. Bjornsson E, Kilander A, Olsson R. CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver. 1999;19:501-508.
36. Fisher A, Theise ND, Min A, et al. CA19-9 does not predict cholangiocarcinoma in patients with primary sclerosing cholangitis undergoing liver transplantation. Liver Transpl Surg. 1995;1: 94-98.